Meet the Team
Our team combines a deep level of scientific and industry experience with a strong commitment to making an impact and saving lives with the innovative work we do to address infectious diseases.
Ted Schroeder joined Nabriva Therapeutics plc in July 2018. During the last 30 years, he has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, Ted served as president, chief executive officer and director of Zavante Therapeutics until its acquisition by Nabriva Therapeutics in 2018. Ted co-founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol-Myers Squibb. He currently serves on the board of Cidara Therapeutics (Nasdaq: CDTX), Otonomy (Nasdaq: OTIC) and Collegium Pharmaceutical (Nasdaq: COLL). He is a former chair of BIOCOM, the Southern California life sciences trade association and in 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University.
Robert Crotty joined Nabriva Therapeutics in June 2017. He has over a decade of experience in the pharmaceutical and biopharmaceutical industries, most recently as Vice President, General Counsel, Chief Compliance Officer, and Secretary at Vernalis Therapeutics, Inc. Robert has a broad legal skill set with experience in corporate governance, securities filings, financing, business development, corporate law, and commercial compliance. Previously, he worked in the life sciences industry with positions at Dendreon Corp., NPS Pharmaceuticals, and ImClone Systems Inc. After law school, Robert worked at two law firms, Morgan, Lewis & Bockius and Norton Rose Fulbright.
Mr. Crotty obtained his law degree from the University of Pennsylvania and his undergraduate degree from Princeton University.
Steven Gelone joined Nabriva Therapeutics in December 2014. Over the past 20 years, Steve has been involved in all stages of drug development and commercialization. He has served as Head of Clinical Research and Development at Spark Therapeutics, as well as Vice President of Development at ViroPharma Inc., (now Shire). Previous roles include leadership positions with GSK, Vicuron Pharmaceuticals, and Temple University Schools of Pharmacy and Medicine. He has a Bachelor of Sciences and Doctorate in Pharmacy degree from Temple University in Philadelphia.
Francesco Maria Lavino joined Nabriva Therapeutics in July 2017, bringing nearly two decades of pharmaceutical sales and marketing experience to his role. The last half of his career has been focused on anti-infective medications administered primarily in the hospital setting. He most recently served as AVP, Global Brand Leader Anti-Infective Portfolio at Merck & Co. Inc. (known as MSD outside the United States), where he was responsible for the development and implementation of the global marketing strategy for the whole Merck anti-bacterial portfolio. Prior to this role, Francesco was Vice President of International Marketing for the Anti-Infectives Portfolio at Cubist Pharmaceuticals, held various roles at Merck including global brand leadership for the company’s antifungal portfolio and positions in marketing and sales, both at regional and country levels. Francesco began his career in pharmaceutical sales at UCB Pharma and 3M in Italy. He has a BA in Pharmacy from the Federico II University of Napoli, Italy and an MBA from SDA Bocconi School of Management in Milan, Italy.
Jennifer Schranz, MD, joined Nabriva Therapeutics in March 2018 and leads their clinical development and medical affairs teams. She has nearly two decades of experience in clinical development and medical affairs working with small molecules, biologics, and vaccines in both small and large pharmaceutical companies. Dr. Schranz was most recently the rare disease global development team lead at Shire plc where she oversaw clinical development, regulatory and life cycle management activities for the company’s hereditary angioedema franchise. She was previously vice president, clinical research at ViroPharma and prior to that vice president clinical research at Cempra. Earlier in her career, she held positions of increasing responsibility in clinical development and medical affairs at several pharmaceutical companies, including Wyeth (now Pfizer), Vicuron, GlaxoSmithKline, and Merck & Co. Inc.. Dr. Schranz earned an M.D. from the University of Toronto, where she completed her internal medicine training and was a fellow in infectious diseases.
Gary Sender joined Nabriva in 2016. He has over 25 years of financial leadership experience in the pharmaceutical and biopharmaceutical industries. He came to Nabriva from Synergy Pharmaceuticals where he was their CFO and Executive Vice President. From 2009 to 2015, Mr. Sender served as Senior Vice President, Finance at Shire plc. supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shire’s $6 billion Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases, and M&A. Prior to joining Shire, he was the founding CFO of Tengion, a biotechnology company in the field of Regenerative Medicine. Mr. Sender spent 15 years in a number of leadership roles within Merck, including Investor Relations, M&A Finance, Treasury and Divisional Financial Management. He serves on the Board of Directors of Schrödinger, Inc and chairs its Audit Committee. Mr. Sender holds a bachelor’s degree in Finance and Information Systems from Boston University and an MBA with a concentration in Finance from Carnegie-Mellon University.
SV LIFE SCIENCES
Daniel Burgess – Chairman
Mr. Burgess is has served on our board of directors since June 23, 2017. Mr. Burgess was a member of the supervisory board of Nabriva Austria and served as its chairman from October 2016 until the Redomiciliation. Mr. Burgess has been a venture partner at SV Health Investors (SV) since 2014. Mr. Burgess has also served as the president and the chief executive officer of Therini Bio, Inc., a private therapeutics company, since May 2019. He was previously president and chief executive officer of Rempex Pharmaceuticals, an antibiotics company he co‑founded in 2011 and that was subsequently sold to The Medicines Company (now Novartis AG) in 2013. Prior to this, Mr. Burgess was president and chief executive officer of Mpex Pharmaceuticals from 2007 until its acquisition by Aptalis Inc. (now AbbVie Inc.) in 2011. Prior to his time at Mpex, Mr. Burgess served in various senior operating roles for other biotechnology companies. In addition, he serves as a member of the boards of directors of Cidara Therapeutics, Inc., a public biotechnology company; Arbutus Biopharma Corp., a public biotechnology company; and several private healthcare companies. Mr. Burgess was a member of the board of directors of Santarus, Inc., from 2004 until its acquisition in 2014 by Salix Pharmaceuticals Inc., a publicly traded pharmaceutical company. He received his B.A. in economics from Stanford University and an M.B.A. from Harvard University. We believe Mr. Burgess is qualified to serve as a director because of his expertise and experience as an executive in the pharmaceutical industry, his service on other boards of directors and his educational background.
NABRIVA THERAPEUTICS PLC.
Mr. Schroeder has served on our board of directors and as chief executive officer since July 24, 2018. During the last 30 years, Mr. Schroeder has been focused on drug development and commercialization in both large and small pharmaceutical companies. Most recently, he served as president, chief executive officer and director of Zavante Therapeutics from June 2015 until its acquisition by Nabriva Therapeutics in July 2018. Mr. Schroeder co‑founded Cadence Pharmaceuticals in 2004 and previously held leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals and earlier in his career, Bristol‑Myers Squibb. He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. He is a former chair of BIOCOM, the California life sciences trade association and in 2014, he was named the EY Entrepreneur of the Year for the San Diego region and was listed as a national finalist. He received a bachelor’s degree in management from Rutgers University. We believe Mr. Schroeder is qualified to serve as a director because of his expertise and experience as an executive in the pharmaceutical industry, his service on other boards of directors and his educational background.
Ms. Bourdow has served on our board of directors since June 23, 2017. Ms. Bourdow has been the president, the chief executive officer, and member of the board of directors of Trevena, Inc., a publicly-traded biopharmaceutical company, since October 2018. She has served in various senior positions at Trevena since May 2015. She joined Trevena as chief commercial officer and was appointed executive vice president and chief operating officer in January 2018. Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for acute care hospital pharmaceuticals. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Ms. Bourdow also serves as a director of Sesen Bio, Inc., a publicly traded pharmaceutical company. Ms. Bourdow holds a B.A. degree from Hendrix College and an M.B.A. from Southern Illinois University. We believe Ms. Bourdow is qualified to serve as a director due to her extensive experience in the biopharmaceutical industry, including her experience with anti‑infectives and with the commercialization of new drugs.
Dr Broom has served on our board of directors since June 23, 2017. Dr. Broom has served as the chief executive officer of Pulmotect, Inc., a private biotechnology company, since September 2019. Dr. Broom was previously our chief executive officer from April 12, 2017 until July 24, 2018, and the chief executive officer of Nabriva Austria from August 2014 until the Redomiciliation. Prior to joining Nabriva Austria, he served as chief scientific officer at ViroPharma Incorporated from 2004 until it was acquired by Shire plc in 2014. Dr. Broom served as vice president of clinical development and medical affairs in Europe for Amgen Inc. from 2000 to 2003 and previously held several leadership positions with Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline). Dr. Broom served as a member of the board of directors of NPS Pharmaceuticals, Inc. from 2009 until its acquisition by Shire in 2015. He is a member of the U.K. Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine. Dr. Broom received his B.Sc. from University College, London and M.B.B.S. from St. George's Hospital Medical School, London. We believe that Dr. Broom is qualified to serve as a director due to his extensive experience in all stages of drug development and commercialization.
TALBOT ADVISORS LLC
George Talbot, MD, FACP, FIDSA
Dr. Talbot has served on our board of directors since June 23, 2017. Dr. Talbot previously served on the supervisory board of Nabriva Austria from 2009 until the Redomiciliation. Dr. Talbot has been the principal at Talbot Advisors LLC, a biopharmaceutical company consultancy, since 2007 and prior to that, from 2000 to 2006. From 2006 to 2007, he served as chief medical officer and executive vice president of Cerexa, Inc. prior to its acquisition by Forest Laboratories, Inc. Dr. Talbot also worked closely with Calixa Therapeutics, Inc. and Durata Therapeutics, Inc., prior to their acquisitions by Cubist Pharmaceuticals, Inc. and Actavis plc, respectively. He was an initial member of the Infectious Diseases Society of America’s Antimicrobial Availability Task Force (“Bad Bugs, No Drugs”) and recently completed a seven‑year tenure as co‑chair of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Projects for Endpoint Development in Acute Bacterial Skin and Skin Structure Infections, Community‑acquired Bacterial Pneumonia, and Hospital‑acquired Bacterial Pneumonia/Ventilator‑associated Bacterial Pneumonia, which made evidence‑based recommendations to the Food and Drug Administration for its Guidance development in these indications. Dr. Talbot received his B.A. from Wesleyan University, his M.D. from the Yale University School of Medicine, and his Infectious Diseases fellowship training at the University of Pennsylvania. After serving as a faculty member of the Infectious Diseases Section at the University of Pennsylvania, he joined the anti‑infectives group at Rhone‑Poulenc‑Rorer in 1990. We believe that Dr. Talbot is qualified to serve as a director due to his education, training and extensive experience in the biopharmaceutical industry.
Charles Rowland, Jr., CPA
Mr. Rowland has served on our board of directors since June 23, 2017. Mr. Rowland previously served on the supervisory board of Nabriva Austria from January 2015 until the Redomiciliation. Mr. Rowland served as chief executive officer of Aurinia Pharmaceuticals Inc. from April 2016 to January 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated from 2008 until it was acquired by Shire plc in 2014. Prior to joining ViroPharma, Mr. Rowland served as executive vice president and chief financial officer, as well as interim co‑chief executive officer, for Endo Pharmaceuticals Inc. from 2006 to 2008 and chief financial officer at Biovail Corporation from 2004 to 2006. He previously held finance and operational positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia, Novartis International AG and Bristol‑Myers Squibb Company. Mr. Rowland currently serves as a member of the board of directors for Blueprint Medicines Corporation, a public biopharmaceutical company, Viking Therapeutics, a public, clinical‑stage biopharmaceutical company, and Orchard Therapeutics, a public, clinical‑stage biopharmaceutical company. In addition, Mr. Rowland serves as a member of the board of directors for Generation Bio, a privately held biopharmaceutical company. Previously, he served on the board of directors at Idenix Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Bind Therapeutics Inc. and Aurinia Pharmaceuticals Inc. Mr. Rowland received his B.S. from Saint Joseph’s University and M.B.A. from Rutgers University. We believe that Mr. Rowland is qualified to serve as a director due to his extensive experience in pharmaceutical operations and all areas of finance and accounting.
Mr. Webster has served on our board of directors since June 23, 2017. Mr. Webster previously served on the supervisory board of Nabriva Austria from October 2016 until the Redomiciliation. Mr. Webster served as the chief financial officer of Spark Therapeutics from July 2014 until its acquisition by Roche Holdings, Inc. in December 2019. He was previously senior vice president and chief financial officer of Optimer Pharmaceuticals, Inc. from June 2012 until its acquisition by Cubist Pharmaceuticals in November 2013. Prior to this, Mr. Webster served as senior vice president and chief financial officer of Adolor Corporation, also acquired by Cubist, from 2008 to 2011. Previously, Mr. Webster served as managing director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). He also was a co‑founder and served as president and chief executive officer of Neuronyx, Inc. Prior to this, Mr. Webster held positions of increasing responsibility, including as director, Investment Banking Division, Health Care Group, for PaineWebber Incorporated. Mr. Webster is currently a member of the board of directors of Viking Therapeutics, Inc. and NextCure, Inc. He holds an A.B. in economics from Dartmouth College and an M.B.A. from the University of Pennsylvania. We believe that Mr. Webster is qualified to serve as a director due to his extensive experience in the biopharmaceutical industry, particularly his service as a chief financial officer and in other executive management roles.
Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic. Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics. XenletaTM (lefamulin) may be an alternative regimen for patients in need. Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors. Learn more at www.XENLETA.com.
Again, to all the medical professionals, please be safe, take care of yourself and stay well.
CEO, Nabriva Therapeutics
Continue to site
© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland